This statistic shows the ranking of the global top 10 biotech and pharmaceutical companies worldwide, based on revenue. The values are based on a 2025 database. U.S. pharmaceutical company Pfizer was ranked first, with a total revenue of around ** billion U.S. dollars. Biotech and pharmaceutical companiesPharmaceutical companies are best known for manufacturing pharmaceutical drugs. These drugs have the aim to diagnose, to cure, to treat, or to prevent diseases. The pharmaceutical sector represents a huge industry, with the global pharmaceutical market being worth around *** trillion U.S. dollars. The best known top global pharmaceutical players are Pfizer, Merck, and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Most of these companies are involved not only in pure pharmaceutical business, but also manufacture medical technology and consumer health products, vaccines, etc. There are both pure play biotechnology companies and pharmaceutical companies which among other products also produce biotech products within their biotechnological divisions. Most of the leading global pharmaceutical companies have biopharmaceutical divisions. Although not a pure play biotech firm, Roche from Switzerland is among the companies with the largest revenues from biotechnology products worldwide. In contrast, California-based company Amgen was one of the world’s first large pure play biotech companies. Biotech companies use biotechnology to generate their products, most often medical drugs or agricultural genetic engineering. The latter segment is dominated by companies like Bayer CropScience and Syngenta. The United Nations Convention on Biological Diversity defines biotechnology as follows: "Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use." In fact, biotechnology is thousands of years old, used in agriculture, food manufacturing and medicine.

NOTE: This dataset replaces a previous one. Please see below. Chicago residents who are up to date with COVID-19 vaccines by Healthy Chicago Equity Zone (HCEZ), based on the reported address, race-ethnicity, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). Healthy Chicago Equity Zones is an initiative of the Chicago Department of Public Health to organize and support hyperlocal, community-led efforts that promote health and racial equity. Chicago is divided into six HCEZs. Combinations of Chicago’s 77 community areas make up each HCEZ, based on geography. For more information about HCEZs including which community areas are in each zone see: https://data.cityofchicago.org/Health-Human-Services/Healthy-Chicago-Equity-Zones/nk2j-663f “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: ·Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of a previous dataset, which cover doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-Region-Age-and-Race-Ethni/n7f2-e2kq. Data notes: Weekly cumulative totals of people up to date are shown for each combination of race-ethnicity and age group within an HCEZ. Note that each HCEZ has a row where HCEZ is “Citywide” and each HCEZ has a row where age is "All" and race-ethnicity is “All Race/Ethnicity Groups” so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity within an HCEZ) who are up to date, divided by the estimated number of people in that subgroup. Population counts are from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group within an HCEZ. All coverage percentages are capped at 99%. Summing all race/ethnicity group populations to obtain citywide populations may provide a population count that differs slightly from the citywide population count listed in the dataset. Differences in these estimates are due to how community area populations are calculated. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccinati

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

a - it is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of Confidentiality Please note that the identification of individuals is also a breach of the common law duty of confidence. An individual who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. Question 1 How many claims have been made to the VDPS due to an adverse reaction to a covid vaccine to date? 16,824 claims have been received by the Vaccine Damage Payment Scheme (VDPS). Question 2– How many claimants have been notified of an outcome? 8,806 claimants have been notified of an outcome. Question 3 – Please provide a breakdown of the vaccines involved in the claims that have received an outcome? Of the 8,806 claims which have received an outcome, 4,107 relate to AstraZeneca, 3,034 relate to Pfizer, 445 relate to Moderna and 1,220 relate to other vaccines, or more than one COVID-19 vaccine and therefore we are unable to categorise them. For example, where a claim relates to an initial vaccine from one manufacturer and a booster from another. Question 4 – How many claims have been successful? Please provide a breakdown of which vaccine were used in the claims awarded. Since disclosure of FOI-02252 whereby 188 claimants were notified they were entitled to a Vaccine Damage Payment, this number has increased by fewer than 5. Of the total number of successful claimants, fewer than five were Pfizer and Moderna and the remaining claims were AstraZeneca. Therefore, as detailed above in accordance with section 40 (2) and section 41 of FOIA, we are unable to provide an updated breakdown by manufacturer. Question 5– How many claims have been rejected / unsuccessful? Please be advised since the disclosure of FOI-02252 where we disclosed 7,748 claims have been rejected, and a further 716 did not meet the criteria for medical assessment, these figures have increased by fewer than five. We have therefore decided not to disclose this exact figure under section 40 (2) and section 41 of the FOIA because the small changes in numbers when compared to figures provided previously could result in claimants being identified. Details of these exemptions are outlined above. Question 6a – What are the reasons for claims being rejected (causation, not meeting 60% threshold, ineligible to claim.) Please provide numbers? Please provide a breakdown of which vaccine was used in the claims when causation was accepted.